Sino Biopharmaceutical Ltd. is a leading pharmaceutical company based in Hong Kong. With a high ESG risk rating score of 31.4, it is considered a high-risk investment. Since its listing on the Hong Kong Stock Exchange in 2000, Sino Biopharmaceutical has grown to become one of the largest Chinese drugmakers. The company has transitioned from generic drug manufacturing to focus on innovative drugs in response to the Chinese government's volume-based procurement policy for the healthcare industry. Currently, 37.8% of the total revenue of Sino Biopharmaceutical comes from a mix of innovative drugs and biosimilar drugs. The company's main revenue drivers are oncology medicines, hepatitis treatments, surgery/analgesia, respiratory medications, and cardio-cerebral vascular therapies.